Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen

Cancer Research

Volumn 66, Issue 6, 2006, Pages 3214-3221

  Kovtun, Yelena V ^a   Audette, Charlene A ^a   Ye, Yumei ^a   Xie, Hongsheng ^a   Ruberti, Mary F ^a   Phinney, Sara J ^a   Leece, Barbara A ^a   Chittenden, Thomas ^a   Blättler, Walter A ^a   Goldmacher, Victor S ^a  

^a IMMUNOGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIBODY CONJUGATE; ANTIGEN; CALICHEAMICIN; GEMTUZUMAB OZOGAMICIN; MAYTANSINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HUC242; RACHELMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; BYSTANDER EFFECT; CANCER INHIBITION; CELL KILLING; CELL POPULATION; COVALENT BOND; CYTOTOXICITY; DISULFIDE BOND; DNA ALKYLATION; DRUG EFFICACY; GENETIC HETEROGENEITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; COLONIC NEOPLASMS; CROSS-LINKING REAGENTS; FEMALE; HT29 CELLS; HUMANS; IMMUNOCONJUGATES; MAYTANSINE; MICE; MICE, SCID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33644787435     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3973     Document Type: Article

References (22)

1. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23:1137-46.
2. Payne G. Progress in immunoconjugate cancer therapeutics. Cancer Cell 2003;3:207-12.
3. Goldmacher VS, Blatter WA, Lambert JM, Chari RVJ. Immunotoxins and antibody-drug conjugates for cancer treatment. In: Muzykantov VTV, editor. Biomedical aspects of drug targeting. Boston: Kluwer Academic Publishers; 2002. p. 291-309.
4. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 2005;5:543-9.
5. Helft PR, Schilsky RL, Hoke FJ, et al. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res 2004;10:4363-8.
6. Tolcher AW, Ochoa L, Hammond LA, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003;21: 211-22.
7. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7:1490-6.
8. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750-63.
9. Muldoon LL. Effect of antigenic heterogeneity on the efficacy of enhanced delivery of antibody-targeted chemotherapy in a human lung cancer intracerebral xenograft model in rats. Neurosurgery 2003;53:1406-12.
10. Muldoon LL, Neuwelt EA. BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models. J Neurooncol 2003;65:49-62.
11. Liu C, Tadayoni BM, Bourret LA, et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci U S A 1996;93:8618-23.
12. Johnson RK, Wong J, Sucheki P, et al. Role of a bystander effect in the efficacy of SB-408075, an antibody-maytansinoid complex, in colon carcinoma xenografts. Proc Am Assoc Cancer Res 2000;41:1926.
13. Chari RV, Martell BA, Gross JL, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992;52:127-31.
14. Chari RV, Jackel KA, Bourret LA, et al. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res 1995;55:4079-84.
15. Roguska MA, Pedersen JT, Keddy CA, et al. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci U S A 1994;91:969-73.
16. Xie H, Audette C, Hoffee M, Lambert JM, Blattler WA. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-1), and its two components in mice. J Pharmacol Exp Ther 2004;308:1073-82.
17. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. In press 2006.
18. Greiner JW. Modulation of antigen expression in human tumor cell populations. Cancer Invest 1986;4: 239-56.
19. Christiansen J, Rajasekaran AK. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther 2004;3:1493-501.
20. Cheng JD, Rieger PT, von Mehren M, Adams GP, Weiner LM. Recent advances in immunotherapy and monoclonal antibody treatment of cancer. Semin Oncol Nurs 2000;16:2-12.
21. Drewinko B, Patchen M, Yang LY, Barlogie B. Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. Cancer Res 1981;41:2328-33.
22. Rao PN, Freireich EJ, Smith ML, Loo TL. Cell cycle phase-specific cytotoxicity of the antitumor agent maytansine. Cancer Res 1979;39:3152-5.